Idenix Pharmaceuticals Reports Second Quarter and Six Month 2012 Financial Results and HCV Program Update
08 août 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Prices Public Offering of Common Stock
02 août 2012 09h22 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
31 juil. 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG
31 juil. 2012 07h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
IDX719 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
25 juil. 2012 08h30 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 25, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
03 juil. 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 3, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 7th Annual JMP Securities...
Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719
19 juin 2012 16h06 HE
|
Idenix Pharmaceuticals
In an Interim Analysis From an Ongoing Phase IIb Clinical Trial of IDX184, an HCV Nucleotide Inhibitor, 89% of Patients Who Completed an Additional 12 Weeks of Pegylated Interferon Plus Ribavirin...
Idenix Pharmaceuticals to Present at the Wells Fargo Securities 2012 Healthcare Conference
13 juin 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will participate in a fireside chat at the Wells Fargo...
Idenix Pharmaceuticals Reports First Quarter 2012 Financial Results and HCV Development Program Progress
02 mai 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
30 avr. 2012 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Deutsche Bank 37th...